Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $69 | $75 | $93 | $203 |
| Short-Term Investments | $384 | $180 | $368 | $136 |
| Receivables | $142 | $144 | $165 | $149 |
| Inventory | $54 | $77 | $92 | $86 |
| Other Curr. Assets | $36 | $17 | $16 | $27 |
| Total Curr. Assets | $686 | $493 | $734 | $602 |
| Property Plant & Equip (Net) | $12 | $14 | $15 | $17 |
| Goodwill | $117 | $117 | $117 | $118 |
| Intangibles | $522 | $600 | $702 | $785 |
| Long-Term Investments | $0 | $17 | $94 | $119 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $32 | $38 | $40 | $49 |
| Total NC Assets | $682 | $785 | $968 | $1,088 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,368 | $1,278 | $1,703 | $1,689 |
| Liabilities | – | – | – | – |
| Payables | $5 | $2 | $11 | $9 |
| Short-Term Debt | $7 | $8 | $409 | $6 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $281 | $280 | $269 | $300 |
| Total Curr. Liab. | $292 | $290 | $688 | $315 |
| LT Debt | $27 | $33 | $36 | $421 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $5 | $25 | $50 | $85 |
| Other NC Liab. | $8 | $8 | $43 | $52 |
| Total NC Liab. | $40 | $66 | $128 | $558 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $34 | $42 | $43 | $48 |
| Total Liabilities | $332 | $356 | $816 | $873 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | $556 | $483 | $481 | $380 |
| AOCI | -$0 | -$1 | -$3 | $2 |
| Other Equity | $479 | $439 | $408 | $434 |
| Total Equity | $1,036 | $922 | $886 | $816 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,368 | $1,278 | $1,703 | $1,689 |
| Net Debt | -$35 | -$34 | $352 | $224 |